Agents for treating disorders involving modulation of ryanodine receptors

a technology of ryanodine receptor and agent, which is applied in the field of agents for treating disorders involving modulation of ryanodine receptor, can solve the problems of limited therapeutic utility of drugs, and achieve the effect of modulating the amount of ryanodine bound calstabin and preventing or treating a leakage in ryr

Inactive Publication Date: 2013-10-24
ARMGO PHARMA
View PDF2 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0036]The present invention further provides methods of treating or preventing various disorders, diseases and conditions associated with RyRs, such as cardiac, musculoskeletal, cognitive, CNS and neuromuscular disorders and diseases, comprising administering to a subject in need of such treatment an amount of a compound of Formula (I) or a salt thereof, effective to prevent or treat a disorder or disease associated with an RyR. The present invention also provides a method of preventing or treating a leak in RyR (including RyR1, RyR2 and RyR3) in a subject, including administering to the subject an amount of a compound of Formula (I) or a salt thereof, effective to prevent or treat a leak in RyR.
[0037]In addition, the present invention provides a method of modulating the binding of RyRs and calstabins in a subject, including administering to the subject an amount of a compound of Formula (I) or a salt thereof, effective to modulate the amount of RyR-bound calstabin.

Problems solved by technology

WO 2007 / 024717 describes structurally similar compounds, however, as further described herein, these compounds have been found to be highly unstable and thus their therapeutic utility as drugs is limited.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Agents for treating disorders involving modulation of ryanodine receptors
  • Agents for treating disorders involving modulation of ryanodine receptors
  • Agents for treating disorders involving modulation of ryanodine receptors

Examples

Experimental program
Comparison scheme
Effect test

example 1

Synthesis

Instruments:

[0107]NMR: Bruker AVANCE III 400 or Varian Mercury 300

[0108]LC / MS: Waters Delta 600 equipped with Autosampler 717Plus, Photo Diode Array Detector 2996, and Mass Detector 3100, or Shimadzu 210

General procedure for the alkylation of 7-methoxy-2,3,4,5-tetrahydrobenzo[f][1,4]thiazepine (“Amine”).

[0109]Amine (structure shown above) (1 mmol) was dissolved in 3 ml dichloromethane. To the solution was added alkylation reagent (1 mmol), followed by N,N-diisopropylethylamine (0.34 ml, 2 mmol). The mixture was stirred at room temperature overnight. The solution was loaded onto column directly and eluted with hexane / EtOAc (2:1, v / v).

Compound 2

[0110]Methyl 3-((7-methoxy-2,3-dihydrobenzo[f][1,4]thiazepin-4(5H)-yl)methyl)benzoate. 1HNMR (300 MHz, CDCl3): 7.96 (m, 2H), 7.46 (m, 3H), 6.70 (dd, J=8.4 Hz, 3.0 Hz, 1H), 6.50 (d, J=2.7 Hz, 1H), 4.09 (s, 2H), 3.90 (s, 3H), 3.72 (s, 3H), 3.57 (s, 2H), 3.35 (m, 2H), 2.72 (m, 2H). MS: 344(M+1)

Compound 3

[0111]Methyl 4-((7-methoxy-2,3-dihy...

example 2

Binding of Calstabin2 to PKA-Phosphorylated RyR2

[0141]Cardiac SR membranes were prepared as previously described (Marx et al., 2000; Kaftan et al., Circ. Res., 1996, 78:990-97). Immunoblotting of microsomes (50 μg) was performed as described, with anti-calstabin antibody (1:1,000) (Jayaraman et al., J. Biol. Chem., 1992, 267:9474-77) for 1 hr at room temperature (Reiken et al., Circulation, 107:2459-66, 2003). After incubation with HRP-labeled anti-rabbit IgG (1:5,000 dilution; Transduction Laboratories, Lexington, Ky.), the blots were developed using ECL (Amersham Pharmacia, Piscataway, N.J.) and detected on x-ray film, or exposed to secondary antibodies labeled with infrared Dye and visualized on equipment from Li-Cor Biosciences (model Odyssey). Unless otherwise stated, compounds were tested at a concentration of 100 nM. A representative calstabin2 binding assay is presented below.

[0142]A. PKA phosphorylation of cardiac sarcoplasmic reticulum (CSR)

[0143]B. Reaction mixture was se...

example 3

Binding of Calstabin1 to PKA-Phosphorylated RyR1

[0173]SR membranes from skeletal muscle were prepared in a manner similar to Example 2, and as further described in US patent application publication No. 2004 / 0224368, the contents of which are incorporated by reference herein. Immunoblotting of microsomes (50 μg) was performed as described, with anti-calstabin1 antibody (Zymed) (1:1,000). The blots were developed and quantified as described in Example 2.

[0174]FIG. 1C depicts an immunoblot with calstabin1 antibody showing binding of calstabin1 to PKA phosphorylated RyR1 in the absence (Neg) or presence of the indicated concentrations of compound 1 or compound 4. (Pos): calstabin binding to non-PKA phosphorylated RyR1. S36 is used as a control. As shown, compound 1 and compound 4 prevented the dissociation of calstabin1 from PKA phosphorylated RyR1 and / or enhanced the (re)binding of calstabin1 to PKA-phosphorylated RyR1 in a dose-dependent manner, with an estimated EC50 of about 100 nM ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
PKAaaaaaaaaaa
PKAaaaaaaaaaa
frequenciesaaaaaaaaaa
Login to view more

Abstract

The present invention relates to 1,4-benzothiazepine derivatives and their use to treat conditions, disorders and diseases associated with ryanodine receptors (RyRs) that regulate calcium channel functioning in cells. The invention also discloses pharmaceutical compositions comprising the compounds and uses thereof to treat diseases and conditions associated with RyRs, in particular cardiac, musculoskeletal and central nervous system (CNS) disorders.

Description

FIELD OF THE INVENTION[0001]The present invention relates to 1,4-benzothiazepine derivatives and their use to treat disorders and diseases associated with ryanodine receptors (RyRs) that regulate calcium channel functioning in cells. The invention also discloses pharmaceutical compositions comprising these compounds and uses thereof to treat diseases and conditions associated with RyRs, in particular cardiac, skeletal muscular and central nervous system (CNS) disorders.BACKGROUND OF THE INVENTION[0002]The sarcoplasmic reticulum (SR) is a structure in cells that functions, among other things, as a specialized intracellular calcium (Ca2+) store. RyRs are channels in the SR, which open and close to regulate the release of Ca2+ from the SR into the intracellular cytoplasm of the cell. Release of Ca2+ into the cytoplasm from the SR increases cytoplasmic Ca2+ concentration. Open probability of RyRs refers to the likelihood that a RyR is open at any given moment, and therefore capable of r...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(United States)
IPC IPC(8): C07D285/36A61K31/554A61K31/7088
CPCC07D285/36A61K31/7088A61K31/554C07D281/10C07D417/10A61P11/00A61P13/00A61P13/02A61P13/12A61P19/00A61P19/02A61P19/08A61P21/00A61P21/04A61P25/00A61P25/14A61P25/16A61P25/22A61P25/24A61P25/28A61P29/00A61P35/00A61P35/04A61P37/02A61P37/06A61P43/00A61P9/00A61P9/04A61P9/06A61P9/10A61P9/12A61P3/10Y10S530/841C07C57/15
Inventor YAN, JIAMINGBELVEDERE, SANDROWEBB, YAELBERTRAND, MARKVILLENEUVE, NICOLE
Owner ARMGO PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap